v3.25.1
Long-Term Investments (Details) - USD ($)
3 Months Ended 12 Months Ended
Jan. 01, 2025
Oct. 31, 2021
Mar. 31, 2025
Dec. 31, 2024
Dec. 31, 2022
Mar. 14, 2024
Long-Term Investments [Line Items]            
Percentage of common stock shares   51.00%        
Aggregate amount         $ 2,688,578  
Prepayment amount         $ 1,895,556  
Converted shares     994,450      
Common stock, shares authorized     100,000,000 100,000,000    
Ordinary shares issued     15,378,305 13,868,484   1,610,700
Ordinary shares outstanding     15,378,305 13,868,484    
Payment to joint venture   $ 150,000        
BioFirst Corporation [Member]            
Long-Term Investments [Line Items]            
Percentage of common stock shares     18.68% 18.68%    
Prepayment amount       $ 1,124,842    
Ordinary shares issued   3,049        
Ordinary shares outstanding   3,049        
Rgene Corporation (the “Rgene”) [Member]            
Long-Term Investments [Line Items]            
Percentage of common stock shares 37.00%   26.65%      
BioLite Japan K.K. [Member]            
Long-Term Investments [Line Items]            
Percentage of common stock shares   49.00%        
Common stock, shares authorized   10,000        
Payment to joint venture   $ 150,000        
BioLite JP [Member]            
Long-Term Investments [Line Items]            
Owned shares   1,494        
Common Stock [Member] | Lucidaim Co Ltd [Member]            
Long-Term Investments [Line Items]            
Owned shares   1,555